http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016525528-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-80 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D275-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C55-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12 |
| filingDate | 2014-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2016525528-A |
| titleOfInvention | Amorphous salt of dasatinib |
| abstract | The present invention mainly relates to a salt of dasatinib, wherein the salt is in an amorphous form. The salts described herein preferably comprise a cation of the compound of formula 1 and an anion of a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin. The invention further relates to pharmaceutical compositions comprising such salts. Furthermore, this invention relates to the manufacturing method of the said salt. The present invention also relates to multiple aspects of using the salt or pharmaceutical composition to treat a disease. |
| priorityDate | 2013-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 110.